Fulcrum Therapeutics (NASDAQ:FULC) shares rose over 5% after BofA upgraded ratings to Neutral, citing likelihood of success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback